BRIX1

Across TCGA pan-cancer cohorts, BRIX1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BRIX1 data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher BRIX1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated BRIX1 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

CCRCC, HNSC, and PDAC are the cancer types where BRIX1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.514	0.878	<.001	49	view →
HNSC	DFS	Median	III,IV	0.678	0.885	.004	30	view →
PDAC	OS	Quartile	All	0.378	0.670	.001	29	view →
LSCC	DFS	Quartile	II,III,IV	1.000	0.507	<.001	22	view →
LUAD	OS	Median	All	0.591	0.992	.001	21	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

BRIX1–CCRCC (DFS)

Open the CCRCC breakdown →